Sumary of Scientists detect delayed and reduced antibody responses after BioNTech/Pfizer COVID-19 vaccination in older adults:
- They are at a higher risk of severe coronavirus disease (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pathogen..
- The study, which appeared in the CDC Emerging Infectious Diseases, highlights the importance of nonpharmaceutical measures, such as regular handwashing, wearing face masks, and physical distancing, even if older adults have already received their vaccines..
- The SARS-CoV-2 pandemic has warranted the rapid development and rollout of vaccines, especially for those at high risk of severe illness and death, including older adults and those with underlying health conditions..
- Related Stories The team enrolled participants in two studies performed at Charité–Universitätsmedizin Berlin in Germany..
- Overall, 123 healthcare workers with an average age of 34 and 71 elderly residents in an assisted living facility with an average age of 81 participated in the study..
- To distinguish between vaccine-induced antibody response and convalescent SARS-CoV-2 infection, the team used the SeraSpot Anti-SARS-CoV-2 IgG microarray-based immunoassay..
- At three weeks, the team found that 93 of 107 of the younger participants demonstrated reactive SARS-CoV-2 receptor-binding domain (RBD) IgG, compared to just 16 of the 52 elderly participants..
- Apart from antibody responses, the team also evaluated the SARS-CoV-2 spike-specific T cell responses bn IFN-γ release assay (IGRA) of S1 peptide-stimulated T cells at the 7th week….